MARKET

APTX

APTX

Aptinyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.361
-0.239
-5.19%
Opening 13:34 01/24 EST
OPEN
5.00
PREV CLOSE
4.600
HIGH
5.14
LOW
4.210
VOLUME
880.18K
TURNOVER
--
52 WEEK HIGH
6.10
52 WEEK LOW
2.610
MARKET CAP
137.25M
P/E (TTM)
-2.5345
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of APTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

APTX News

  • Why Aptinyx Stock Soared on Friday
  • MotleyFool.com.4d ago
  • Notable Insider Buys Last Week: Small-Cap Biotechs
  • Benzinga.5d ago
  • Notable Insider Buys Last Week: Small-Cap Biotechs
  • Benzinga.5d ago
  • Aptinyx +10.6% after closing offering, insider buys
  • seekingalpha.01/15 03:59

More

Industry

Pharmaceuticals
-1.46%
Pharmaceuticals & Medical Research
-1.62%

Hot Stocks

Name
Price
%Change

About APTX

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
More

Webull offers Aptinyx Inc (APTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.